17:29 , Nov 16, 2018 |  BC Week In Review  |  Company News

Oxurion, Beta Therapeutics partner to develop heparanase inhibitors

Oxurion N.V. (Euronext:OXUR) and Beta Therapeutics Pty. Ltd. (Canberra, Australia) partnered to develop heparanase inhibitors to treat retinal disorders, including dry age-related macular degeneration (AMD). Oxurion will have an exclusive option to license the heparanase...